BMS’s Opdivo May Be Next Casualty Of US FDA’s Perioperative Trial Redesign Push

 
• By Sarah Karlin-Smith
two sets of business people with giant speaking bubbles that are disconnected and broken showing visual of communication breakdown
The Imfinzi ODAC meeting revealed potentially broader communication problems between the FDA and industry. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards